Evolving Goals in Multiple Myeloma Treatment

EP: 1.Unmet Needs In Multiple Myeloma Management

Now Viewing

EP: 2.Evolving Goals in Multiple Myeloma Treatment

EP: 3.Multiple Myeloma Induction Challenges and Future Options

EP: 4.Optimizing Multiple Myeloma Treatment: Quadruplet Therapy

EP: 5.Real-World Insights: Multiple Myeloma Treatment Challenges

EP: 6.Navigating the Multiple Myeloma Treatment Landscape

EP: 7.Real-world Multiple Myeloma Treatment: Insights and Challenges

EP: 8.The Future of Multiple Myeloma Treatment

EP: 9.ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives

EP: 10.Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.

Richter leads a discussion with experts Krishnan and Abonour on evolving goals and approaches in treating newly diagnosed myeloma patients. Krishnan emphasizes the loftier goals of achieving minimal residual disease–negative remission, especially for younger patients, while balancing toxicity for older, frail patients. The conversation delves into treatment strategies for transplant-ineligible patients, exploring clinical trials, such as SWOG S0777 (NCT00644228) and MAIA (NCT02252172). Abonour highlights the importance of tailoring treatment to individual patient characteristics, considering factors such as neuropathy in choosing between regimens. The experts discuss nuances in administering VRd (bortezomib, lenalidomide, dexamethasone) emphasizing the need for personalized approaches to optimize myeloma control and patient outcomes.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.